Pluri Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Pluri.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	27.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Market Sentiment Around Loss-Making Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Nov 30

Recent updates

Pluri gains as PROTO project receives €7.5M EU grant

Sep 06

Pluristem Therapeutics renames as Pluri

Jul 25

Pluristem Therapeutics (NASDAQ:PSTI) Has Debt But No Earnings; Should You Worry?

Dec 04

We Think Pluristem Therapeutics (NASDAQ:PSTI) Needs To Drive Business Growth Carefully

Aug 18

What Is The Ownership Structure Like For Pluristem Therapeutics Inc. (NASDAQ:PSTI)?

Mar 15

We're Hopeful That Pluristem Therapeutics (NASDAQ:PSTI) Will Use Its Cash Wisely

Feb 08

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pluri has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:PLUR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	1	-22	-17	-16	N/A
6/30/2024	0	-21	-18	-18	N/A
3/31/2024	0	-22	-17	-17	N/A
12/31/2023	0	-24	-19	-18	N/A
9/30/2023	0	-27	-21	-21	N/A
6/30/2023	0	-28	-23	-23	N/A
3/31/2023	0	-31	-29	-28	N/A
12/31/2022	0	-33	-32	-32	N/A
9/30/2022	0	-36	-36	-35	N/A
6/30/2022	0	-41	-37	-37	N/A
3/31/2022	0	-47	-38	-38	N/A
12/31/2021	N/A	-51	-36	-36	N/A
9/30/2021	N/A	-53	-34	-34	N/A
6/30/2021	N/A	-50	-31	-31	N/A
3/31/2021	N/A	-43	-28	-28	N/A
12/31/2020	N/A	-37	-27	-27	N/A
9/30/2020	0	-31	-26	-25	N/A
6/30/2020	0	-29	-27	-26	N/A
3/31/2020	0	-29	-27	-27	N/A
12/31/2019	0	-31	-26	-26	N/A
9/30/2019	0	-34	-28	-28	N/A
6/30/2019	0	-35	-30	-29	N/A
3/31/2019	0	-37	-29	-29	N/A
12/31/2018	0	-28	-28	-28	N/A
9/30/2018	0	-28	-25	-25	N/A
6/30/2018	0	-26	N/A	-21	N/A
3/31/2018	0	-24	N/A	-22	N/A
12/31/2017	0	-30	N/A	-22	N/A
9/30/2017	N/A	-29	N/A	-23	N/A
6/30/2017	N/A	-28	N/A	-22	N/A
3/31/2017	N/A	-27	N/A	-21	N/A
12/31/2016	N/A	-26	N/A	-21	N/A
9/30/2016	3	-24	N/A	-19	N/A
6/30/2016	3	-23	N/A	-19	N/A
3/31/2016	3	-22	N/A	-18	N/A
12/31/2015	3	-22	N/A	-19	N/A
9/30/2015	0	-25	N/A	-21	N/A
6/30/2015	0	-25	N/A	-21	N/A
3/31/2015	0	-26	N/A	-21	N/A
12/31/2014	0	-28	N/A	-20	N/A
9/30/2014	0	-28	N/A	-17	N/A
6/30/2014	0	-27	N/A	-19	N/A
3/31/2014	0	-28	N/A	-19	N/A
12/31/2013	0	-24	N/A	-18	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PLUR's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if PLUR's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if PLUR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if PLUR's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if PLUR's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PLUR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 10:20
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pluri Inc. is covered by 17 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
George Zavoico	B. Riley Securities, Inc.
Jason Kolbert	B. Riley Wealth

Pluri Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$7.00

Price target increased to US$9.75

Price target increased to US$9.75

Price target decreased to US$7.75

Price target lowered to US$8.50

Market Sentiment Around Loss-Making Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Recent updates

Pluri Receives Nasdaq Notification of Non-Compliance with Listing Rule 5550(B)(1)

First quarter 2025 earnings released: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024)

New minor risk - Share price stability

Full year 2024 earnings released

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces CFO Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Third quarter 2024 earnings released: US$1.01 loss per share (vs US$1.53 loss in 3Q 2023)

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)

Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023)

Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022)

Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

Pluri Inc. announced that it has received $8.469323 million in funding

Pluri Inc. announced that it expects to receive $8.170972 million in funding

Price target decreased to US$7.00

High number of new and inexperienced directors

Pluri Receives Non-Compliance Letter from Nasdaq

Pluri Inc. Announces €7.5 Million Non-Dilutive Grant from the European Union’s Horizon Europe Program to Study PLX-PAD Cells for Osteoarthritis Treatment

Pluri gains as PROTO project receives €7.5M EU grant

Pluristem Therapeutics renames as Pluri

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Pluristem Therapeutics Inc. Announces Board Changes

Price target increased to US$9.75

High number of new directors

Price target increased to US$9.75

High number of new directors

Pluristem Therapeutics Inc. and Tnuva Group Appoint Eyal Rosenthal as Chief Executive Officer of Their New Joint Venture

High number of new directors

Chairman recently bought US$145k worth of stock

Pluristem Therapeutics Inc. Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Price target decreased to US$7.75

Pluristem Therapeutics (NASDAQ:PSTI) Has Debt But No Earnings; Should You Worry?

We Think Pluristem Therapeutics (NASDAQ:PSTI) Needs To Drive Business Growth Carefully

Independent Director Isaac Braun has left the company

Insider recently sold US$1.6m worth of stock

Insider recently sold US$102k worth of stock

Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in humans

What Is The Ownership Structure Like For Pluristem Therapeutics Inc. (NASDAQ:PSTI)?

New 90-day low: US$5.58

Earnings beat expectations

We're Hopeful That Pluristem Therapeutics (NASDAQ:PSTI) Will Use Its Cash Wisely

Pluristem Therapeutics launches $30M registered direct offering

Pluristem Therapeutics Inc. Announces Board Appointments

Have Insiders Been Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares?

Pluristem Therapeutics Inc. Enters Collaboration With Innovare R&D to Expand Its ARDS Associated With COVID-19 Program to Mexico

Pluristem expands COVID-19 program in Mexico

Price target lowered to US$8.50

Pluristem Therapeutics Inc. Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

Pluristem - Moment Of Truth

New 90-day high: US$11.40

Insider recently bought US$194k worth of stock

Market Sentiment Around Loss-Making Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. to Present Initial Results from its Phase I HCT Study

Earnings beat expectations

Insider recently bought US$184k worth of stock

Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study

Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event

Insider recently bought US$97k worth of stock